ストックスクリーナーアプリを入手
4.805
2.14%
-0.105
前日終値:
$4.91
開ける：
$4.92
24時間の取引高:
577.89K
Relative Volume:
1.20
時価総額：
$382.70M
収益：
$16.72M
当期純損益:
$-77.80M
株価収益率:
-4.5446
EPS:
-1.0573
ネットキャッシュフロー:
$-43.78M
1週間 パフォーマンス:
-2.14%
1か月 パフォーマンス:
+21.65%
6か月 パフォーマンス:
+82.70%
1年 パフォーマンス:
+441.65%
1日の値動き範囲:
$4.35
$4.98
1週間の範囲:
$4.35
$5.33
52週間の値動き範囲:
$0.75
$5.69
Prelude Therapeutics Inc Stock (PRLD) Company Profile
名前
Prelude Therapeutics Inc
セクター
電話
(302) 467-1280
住所
175 INNOVATION BOULEVARD, WILMINGTON
Compare PRLD vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
4.805 | 382.70M | 16.72M | -77.80M | -43.78M | -1.0573 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-09-19 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2024-06-20 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2024-03-13 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-02-20 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-12-19 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2022-11-21 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-09-09 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-07-29 | 開始されました | Jefferies | Buy |
| 2022-03-15 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-02-28 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2021-10-08 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-07-27 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-04-26 | 開始されました | H.C. Wainwright | Buy |
| 2021-03-09 | 開始されました | Barclays | Overweight |
| 2020-11-20 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-10-20 | 開始されました | BofA Securities | Buy |
| 2020-10-20 | 開始されました | Goldman | Neutral |
| 2020-10-20 | 開始されました | Morgan Stanley | Equal-Weight |
すべてを表示
Prelude Therapeutics Inc (PRLD) 最新ニュース
Prelude Therapeutics Hits New 52-Week High of $5.67, Up 527.79% - MarketsMojo
Citizens reiterates Prelude Therapeutics stock rating on IND filing By Investing.com - Investing.com Canada
Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell 2500 Growth Benchmark - marketscreener.com
Prelude Therapeutics Incorporated(NasdaqGS: PRLD) added to Russell 2000 Index - marketscreener.com
Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell 2000 Growth Benchmark - marketscreener.com
Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell 3000E Growth Benchmark - marketscreener.com
Prelude Therapeutics Incorporated(NasdaqGS: PRLD) added to Russell Microcap Index - marketscreener.com
Prelude Therapeutics Incorporated(NasdaqGS:PRLD) added to Russell Small Cap Completeness Index - marketscreener.com
MapLight Therapeutics appoints two directors to board - Investing.com UK
MapLight Therapeutics appoints two directors to board By Investing.com - Investing.com India
Prelude Therapeutics Inc (PRLD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Prelude Therapeutics (PRLD) Edges Higher, Approaches Key Resistance at $4.60Overvalued Signals - dars.gov.et
Prelude Therapeutics (PRLD) Edges Lower as Stock Tests Key Support LevelADD Alert - dars.gov.et
PRLD Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
Prelude Therapeutics Inc (PRLD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Prelude Therapeutics Inc (PRLD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Prelude Therapeutics Inc (PRLD) Valuation: PE, PB & Fair Value Analysis - TradingKey
Prelude Therapeutics Inc (PRLD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Prelude Therapeutics Inc (PRLD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Prelude Therapeutics Inc (PRLD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Prelude Therapeutics Inc (PRLD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Prelude Therapeutics Inc (PRLD) Institutional Confidence - TradingKey
PRLD Q1 2026 Earnings: EPS Beat Drives Strong Stock ReactionEPS Growth Rate - newsline.com
Market Sentiment Around Loss-Making Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Moomoo
PRLD Q1 2026 Earnings: Narrower Net Loss Beats EstimatesNegative Surprise Momentum - newsline.com
[Form 4] Prelude Therapeutics Inc Insider Trading Activity - Stock Titan
Director at Prelude Therapeutics (PRLD) awarded 38,000 stock options - Stock Titan
Prelude Therapeutics (PRLD) director receives 38,000 stock options at $3.94 strike - Stock Titan
Prelude Therapeutics (PRLD) shareholders back directors, auditor and say-on-pay - Stock Titan
PRLD: All director, auditor, and executive compensation proposals were approved by shareholder vote - TradingView
PRLD: All proposals passed, directors elected, auditor ratified, and no shareholder questions submitted - TradingView
PRLD Stock Price, Quote & Chart | PRELUDE THERAPEUTICS INC (NASDAQ:PRLD) - ChartMill
Prelude Therapeutics Rises Pre-Market With Focus on Two Cancer Drugs - Bez Kabli
Prelude Therapeutics Reports Earnings and Advances Precision Oncology Pipeline - asatunews.co.id
Prelude Therapeutics Reports First Quarter Financial Results and Pipeline Expansion - HarianBasis.co
Goldman Sachs Initiates Coverage on Prelude Therapeutics: What It Could Mean for InvestorsEPS Growth Report - newsline.com
Goldman Sachs Initiates Coverage of Prelude Therapeutics (PRLD) - Yahoo Finance
Prelude Therapeutics Drops 5.5% as Biotech Sector Faces Headwinds – Key Support Levels in FocusBollinger Squeeze - The Legal Advocate
PRLDPrelude Therapeutics Inc Stock Price and Quote - Finviz
Prelude Therapeutics (PRLD) Extends Gains: Support Holds, Resistance in FocusFear Greed Index - The Legal Advocate
PRLD Q1 2026 Earnings: Narrower-Than-Expected Loss as Clinical Pipeline AdvancesOne-Time Gain Impact - newsline.com
Prelude Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update - geneonline.com
Prelude Therapeutics: Current Cash Runway Into 2Q 2028 >PRLD - Moomoo
Prelude Therapeutics Q1 2026 Earnings: Narrowing Losses as Pipeline AdvancesProfit Warning Alert - dars.gov.et
New PROTACs reported in Prelude Therapeutics patent - BioWorld News
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Sahm
Earnings Beat: Prelude Therapeutics Incorporated (NASDAQ:PRLD) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - Yahoo Finance
Goldman Sachs initiates Prelude Therapeutics stock coverage as Early-Stage Biotech - Investing.com India
Prelude Therapeutics (PRLD) price target increased by 11.49% to 7.01 - MSN
Prelude Therapeutics Inc (PRLD) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):